Perspective Therapeutics (CATX) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Perspective Therapeutics (CATX) over the past year, losing 22.4% versus a loss of 29.8%. Over five years, CATX leads with a -56.3% price change compared with -90.6% for RCKT. Perspective Therapeutics is the larger company by market cap ($303.1 million vs $287.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | RCKT |
|---|---|---|
| Share price | $2.66 | $2.62 |
| Market cap | $303.07M | $287.06M |
| 1-day change | -2.03% | -0.57% |
| YTD return | -1.45% | -25.07% |
| 1-year return | -29.79% | -22.42% |
| 5-year return | -56.29% | -90.58% |
| EPS (TTM) | $-1.33 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $5.45 |
| 52-week low | $1.96 | $2.42 |
| Distance from 52-week high | -56.90% | -52.02% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +362.90% | +225.05% |
| Average volume | 1.67M | 1.67M |
| Shares outstanding | 114.15M | 109.77M |
| Employees | 163 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
CATX vs RCKT FAQ
Which is bigger, Perspective Therapeutics or Rocket Pharmaceuticals?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $303.07M compared with $287.06M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, CATX or RCKT?
RCKT returned -22.42% over the past 12 months, compared with -29.79% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.